<DOC>
	<DOCNO>NCT01230138</DOCNO>
	<brief_summary>The purpose trial investigate efficacy safety different dos dose administration FP187 compare placebo treatment patient moderate severe plaque psoriasis .</brief_summary>
	<brief_title>Pivotal Efficacy Safety Registration Trial FP187 Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description>The trial test two different dose level two different daily dosing schedule ( twice daily ( BID ) three time daily ( TID ) ) 20 week treatment . Key effect measure achievement 75 % reduction PASI 20 week safety monitor adverse event safety lab . There 3 active arm : 1 . FP-187 daily dose 750mg divide three dos ( 250mg TID ) 2 . FP-187 daily dose 750mg divided two dos ( 375mg BID ) 3 . FP-187 daily dose 500mg divided two dos ( 250mg BID ) 1 placebo arm . An additional open ( flexible dosing ) treatment arm amend trial</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Patients either sex least 18 year age A clinical diagnosis plaque psoriasis define skin area erythema , induration scaling , body surface area le 10 % total scoring least 10 PASI scale The psoriasis disease stable least 6 month randomization Signed date informed consent Sexually active female childbearing potential must either surgically sterile ( hysterectomy tubal ligation ) use highly effective ( failure rate &lt; 1 % ) medically accept contraceptive method trial well one month trial finish : Systemic contraceptive ( oral , implant , injection ) , Intrauterine device ( IUD ) insert least one month prior study entrance Willingness ability comply trial procedure Patient beside psoriasis disease good general health opinion Investigator , determine medical history , physical examination , vital sign clinical laboratory parameter ( hematology , biochemistry urinalysis ) . Female patient pregnant breastfeed plan become pregnant 7 month treatment start well male patient plan pregnancy partner 7 month treatment start practise unprotected sexual relationship 7 month treatment start Known allergy constituent product test Pustular form psoriasis , erythrodermic guttate psoriasis Known immunosuppressive disease ( e.g. , AIDS/HIV ) Presence another serious progressive disease , accord Investigator may interfere treatment outcome Active skin disease atopic dermatitis , rosacea , lupus erythematosus , inflammatory infectious skin disease , accord Investigator may interfere treatment outcome Use topical medical treatment UVB treatment Use systemic antipsoriatic treatment precede baseline visit Methotrexate , cyclosporine , steroid PUVA treatment within x week ; Biological treatment ( efalizumab , adalimumab , infliximab , etanercept ) within xx week ; Acitretin within x month ; Treatment Fumaderm® DMF contain product past xx week prior baseline visit ; Discontinuation previous treatment Fumaderm® DMF containing product due lack efficacy side effect ; Has within past x week prior baseline visit treat drug influence course psoriasis antimalarial drug , betablockers lithium Has relevant clinical history stomach intestinal problem ( eg gastritis peptic ulcer within last 10 year ) Has liver enzyme measure ( AST , ALT , GammaGT ) high 2x UNL ) Has estimate Creatinine Clearance : &lt; xx ml/min Has leucopenia ( leukocyte count &lt; x/mm3 ) eosinophilia ( count &gt; x/µl ) lymphopenia ( count &lt; x/nl ) . Has protein urine test screen baseline visit Participation another clinical trial last month precede baseline visit participation trial treatment biologicals within x month prior baseline visit Patients involve organisation clinical investigation way dependant investigator sponsor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>